Lotti Dunne

Lotti Dunne is a Research Scientist at Pantherna Therapeutics GmbH, a company focused on developing novel mRNA therapies.23 In her role, she specializes in the development of lipid nanoparticle (LNP) mRNA delivery systems, which are crucial for the company's therapeutic approach.4

Research Focus

Dunne's work primarily involves:

1. Investigating the effects of mRNA therapeutics on strengthening endothelial cells, using primary human endothelial cell cultures.3
2. Contributing to Pantherna's efforts in developing mRNA and LNP technology platforms for a wide spectrum of potential target diseases.1

Recent Activities

In April 2024, Lotti Dunne represented Pantherna Therapeutics at the Delivery of Nucleic Acids conference in Siracusa, Sicily. This event provided her with an opportunity to connect with other professionals in the field and share insights about the company's work.5

Company Context

At Pantherna Therapeutics, Dunne is part of an international team that combines senior industry expertise with junior scientific curiosity to drive innovation in mRNA therapies.2 The company's focus includes:

• Developing the PTXmRNA® technology, which has shown superior results in target protein expression compared to commercially available mRNA.1
• Creating proprietary LNP formulations with various physicochemical attributes for effective drug delivery.1
• Working on organ-selective and cell type-specific LNP delivery systems.1

Lotti Dunne's role as a Research Scientist contributes to these efforts, particularly in the areas of mRNA therapeutics and their delivery mechanisms.